CD38 a biomarker and therapeutic target in non-hematopoietic tumors.
Biomark Med
; 16(5): 387-400, 2022 04.
Article
em En
| MEDLINE
| ID: mdl-35195042
The type II transmembrane glycoprotein CD38 has recently been implicated in regulating metabolism and the pathogenesis of multiple conditions, including aging, inflammation and cancer. CD38 is overexpressed in several tumor cells and microenvironment tumoral cells, associated to migration, angiogenesis, cell invasion and progression of the disease. Thus, CD38 has been used as a progression marker for different cancer types as well as in immunotherapy. This review focuses on describing the involvement of CD38 in various non-hematopoietic cancers.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Imunoterapia
/
Neoplasias
Limite:
Humans
Idioma:
En
Revista:
Biomark Med
Assunto da revista:
BIOQUIMICA
/
MEDICINA
Ano de publicação:
2022
Tipo de documento:
Article
País de afiliação:
México
País de publicação:
Reino Unido